Innovating Novel Therapeutics and Bettering Lives

OUR MISSION

mabwell home 01 hand

Unconventional Antibody Therapeutics

We are striving to improve the lives of people with rare, debilitating diseases by leveraging the promise of science into novel antibody therapeutics.

Our Company

PIPELINE

The Science Behind Our Approach

Following rigorous research and development guidelines, we are advancing antibody drugs that address unmet medical needs. We pinpoint targets, uncover lead molecules, and leverage antibody engineering to boost the chance of favorable outcomes.

PIPELINE
mabwell home 02 genes

What’s Happening
at Mabwell Therapeutics


PRESS RELEASES

August 20, 2021

Mabwell Receives IND Clearance from FDA for Initiating Clinical Trials for its Anti-CD47/PD-L1 Bispecific Antibody

Read more

August 10, 2021

NMPA Accepted IND Application of China’s First Anti-Nectin-4 ADC Drug

Read more

May 8, 2021

First China-made Anti-ST2 Antibody Developed by Mabwell Approved for Clinical Study

Read more

February 5, 2021

Mabwell participated in the Shanghai Biopharmaceutical Industry Innovation Alliance as the Secretary-General

Read more

Want to be part of the journey?